Clinical trials: Prostate Cancer Stage
Prostatic Neoplasms, Castration-Resistant
A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to evaluate the safety and tolerability of JNJ-56021927 in Japanese participants with metastatic castration-resistant prostate cancer (mCRPC- prostate cancer that is resistant to medical [for example.
- Trial name
- NCT02162836
- Testing
- JNJ-56021927
- Where
- 4 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Janssen Pharmaceutical K.K.
Prostate Cancer
Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.
In summary this trial will test whether this new surgical technique can be used to make surgery safer and more effective whilst allowing improved quality of life for patients having surgery for prostate cancer.
- Trial name
- NeuroSAFEPROOF (NCT03317990)
- Testing
- NeuroSAFE procedure, Standard RARP
- Where
- 5 sites in United Kingdom
- Volunteers
- 407 people
- Sponsor
- University College, London
Stage IV Prostate Cancer
Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer
Current therapies for Refractory Stage IV Prostate Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Refractory Stage…
- Trial name
- NCT00003534
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Sponsor
- Burzynski Research Institute
Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer
Bladder cancer is the 4th most common cancer amongst men. If bladder cancer invades the muscle of the bladder or fails local treatments, surgical removal of the bladder (cystectomy) with creation of a new bladder from intestine…
- Trial name
- SPARC (NCT01824329)
- Testing
- Prostate capsule sparing cystectomy, Nerve sparing cystectomy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Prostate Cancer Stage I
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
In Taiwan, about 70% of new incident prostate cancer patients have localized disease. Most patients were detected by PSA screening.
- Trial name
- NCT03789253
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Prostate Cancer
Efficacy and Safety of Zactima™ in Patients With Castration-refractory Metastatic Prostate Cancer
This randomized, double-blind phase II trial is to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer…
- Trial name
- NCT00659438
- Testing
- ZD6474 (Vandetanib), Bicalutamide
- Where
- 5 sites in France
- Volunteers
- 95 people
- Sponsor
- Genzyme, a Sanofi Company
Fatigue, Metastatic Prostate Carcinoma
Resistance Training +/- Creatine for Metastatic Prostate Cancer Patients
This trial studies how well resistance training with or without creatine monohydrate supplement works in improving body composition and health outcomes in patients with prostate cancer that has spread to other places in the body.
- Conditions
- Fatigue, Metastatic Prostate Carcinoma, Sedentary Lifestyle, Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8
- Trial name
- NCT03987217
- Testing
- Creatine Monohydrate, Exercise Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- University of Utah
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00512668
- Testing
- leuprolide acetate, goserelin acetate, bicalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- CASPAR (NCT04455750)
- Testing
- Enzalutamide, Rucaparib camsylate, Leuprolide Acetate
- Where
- 414 sites in United States
- Volunteers
- 61 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate CA
Phase II Randomized Trial of 2 Versus 5 Fraction Prostate Stereotactic Ablative Radiotherapy for Intermediate Risk Prostate Cancer
Prostate cancer is a common cancer, and a significant cause of cancer death in men. There are many potentially curative treatment options for prostate cancers that have not spread.
- Trial name
- ADAPT-25 (NCT06835725)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- British Columbia Cancer Agency
High-Risk Localized Prostate Cancer
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
This research is being done to find out if the study drug, 177Lu-PSMA-617, given before and during standard of care External Beam Radiation Therapy (EBRT) treatment, with a shorter course of Androgen Deprivation Therapy (ADT) (6…
- Trial name
- NCT07550517
- Testing
- EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody
The purpose of this study is to test the safety of the experimental drug, 177Lu-J591 and see what effects (good and bad) it has on your prostate cancer.
- Trial name
- NCT00538668
- Testing
- 117Lu-J591
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087035
- Testing
- docetaxel, erlotinib hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer Metastatic, Prostate Cancer
Castrate Resistant Prostate Cancer Enhertu Therapy
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
- Conditions
- Prostate Cancer Metastatic, Prostate Cancer, CRPC
- Trial name
- CaRPET (NCT06610825)
- Testing
- Enhertu
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Washington D.C. Veterans Affairs Medical Center
Prostate Cancer
Tecemotide (L-BLP25) in Prostate Cancer
This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.
- Trial name
- NCT01496131
- Testing
- Radiation therapy, Goserelin, Cyclophosphamide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- EMD Serono
Prostate Cancer Metastatic
Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)
This is a phase II randomised, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases.
- Trial name
- CRPC (NCT02825628)
- Testing
- Osteodex
- Where
- 8 sites in Estonia, Finland and 2 more
- Volunteers
- 55 people
- Sponsor
- DexTech Medical AB
Cancer
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
The primary purpose of this study is to determine the maximally tolerated dose (MTD) of HGS1036 when used in combination with the standard chemotherapeutic regimens paclitaxel plus carboplatin, cisplatin plus etoposide, or…
- Trial name
- NCT01604863
- Testing
- HGS1036 + Paclitaxel + Carboplatin, HGS1036 + Cisplatin + Etoposide, HGS1036 + Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Prostate Cancer
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to assess the safety and activity of ARN-509 in men with advanced castration resistant prostate cancer.
- Trial name
- NCT01171898
- Testing
- ARN-509 (Phase 1), ARN-509 (Phase 2)
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- Aragon Pharmaceuticals, Inc.
Prostate Cancer
Stereotactic Body Radiotherapy for Prostate Cancer
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of organ confined prostate cancer.
- Trial name
- NCT01352598
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Mercy Research
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
This is a multicenter, open-label, Phase 1 study that will be conducted in two parts. Part 1 is the dose escalation of APG-5918. Part 2 is the dose expansion of APG-5918. APG-5918 will be administered orally.
- Conditions
- Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma
- Trial name
- NCT05415098
- Testing
- APG-5918
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Ascentage Pharma Group Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.